Genmab A/S (NASDAQ:GMAB)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a note issued to investors on Wednesday, TipRanks reports. They presently have a $25.00 price objective on the stock. HC Wainwright’s price target would indicate a potential upside of 10.91% from the stock’s current price.

A number of other analysts have also recently weighed in on the stock. Deutsche Bank cut shares of Genmab A/S from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. ValuEngine upgraded Genmab A/S from a “sell” rating to a “hold” rating in a research note on Tuesday, December 3rd. SunTrust Banks assumed coverage on Genmab A/S in a research report on Monday, January 13th. They issued a “buy” rating for the company. Finally, Zacks Investment Research downgraded Genmab A/S from a “hold” rating to a “sell” rating in a research report on Saturday, January 4th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $23.67.

GMAB traded down $0.44 during trading on Wednesday, hitting $22.54. 3,262 shares of the company’s stock were exchanged, compared to its average volume of 212,194. The company has a current ratio of 18.72, a quick ratio of 18.72 and a debt-to-equity ratio of 0.01. Genmab A/S has a 1 year low of $14.48 and a 1 year high of $24.50. The stock’s 50 day moving average is $22.47. The stock has a market capitalization of $2.98 billion and a price-to-earnings ratio of 5.98.

Genmab A/S (NASDAQ:GMAB) last issued its earnings results on Wednesday, November 6th. The company reported $1.26 EPS for the quarter, beating the Zacks’ consensus estimate of $0.08 by $1.18. Genmab A/S had a net margin of 42.39% and a return on equity of 16.26%. The business had revenue of $158.22 million for the quarter, compared to the consensus estimate of $139.37 million. Sell-side analysts forecast that Genmab A/S will post 0.52 earnings per share for the current year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Redmile Group LLC acquired a new position in Genmab A/S in the 3rd quarter worth $25,297,000. Zimmer Partners LP purchased a new stake in shares of Genmab A/S during the third quarter worth about $15,195,000. Parametric Portfolio Associates LLC acquired a new position in shares of Genmab A/S in the second quarter worth about $6,937,000. Millennium Management LLC acquired a new position in shares of Genmab A/S in the third quarter worth about $6,328,000. Finally, Oppenheimer Asset Management Inc. acquired a new position in shares of Genmab A/S in the third quarter worth about $4,788,000. 19.62% of the stock is owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).

See Also: Learning About the VIX – Volatility Index

Analyst Recommendations for Genmab A/S (NASDAQ:GMAB)

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.